Proliferation is a central independent prognostic factor and target for personalized and risk-adapted treatment in multiple myeloma
Background Proliferation of malignant plasma cells is a strong adverse prognostic factor in multiple myeloma and simultaneously targetable by available (e.g.tubulin polymerase inhibitors) and upcoming (e.g.aurora kinase inhibitors) compounds.Design and Methods We assessed proliferation using gene expression-based indices in 757 samples including in